curb glp 1 Modere | Burn, Curb, Sculpt | Modere Obesity drugs regulate neural systems

Funding This work was supported by Statutory Funds of the Laboratory of Immunoendocrinology, Maj Institute of Pharmacology, Cracow, Poland

Side effect tolerance plays a role

Also noteworthy earlier this month was the publication of a Phase 2 randomized trial in 272 participants without diabetes of orforglipron, an oral GLP-1 agonist, which achieved a 14.7% weight loss (placebo-adjusted 12.3%) at the highest dose With that brief review of the latest trials and drugs, lets turn to clinical outcomes, for which most are taking us back to single agonistGLP-1drugs

Glucose-dependent insulinotropic polypeptide (GIP) Combining GLP-1 with its incretin partner GIP is a promising strategy (Figure 2) under investigation for treating T2D and obesity